Debio 1124 is radio-conjugate compound formed by a second-generation peptide analogue of minigastrin, coupled to the isotope 177Lutetium.

The product is being developed in Medullary Thyroid Cancer (MTC) and is also being studied in Small Cell Lung Cancer (SCLC). Debio 1124 belongs to the emerging class of Peptide Receptor Radionuclide Therapies (PRRT) and has been designed to selectively deliver its payload to tumor cells expressing the Cholecystokinin B Receptor (CCK2R). Importantly, as the compound can also be used as a sensitive diagnostic tool, an initial imaging step allows the selection of patients whose tumor expresses the target receptor and so are expected to benefit from this innovative treatment. In addition to MTC and SCLC, the compound will be further investigated in other tumor types with a high incidence of CCK2R expression

Therapeutic indications
Type of product
  • Phase
    Phase I started
  • Partnering status
    Not partnered

You may also be interested in